Yes.
A prospective, randomized, placebo-controlled clinical study evaluated DIVIRNAM®.
According to the manufacturer, the study demonstrated a significant reduction in viral load for SARS-CoV-2, with even stronger results observed for Influenza A. Publication of the study is pending.